Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antineoplaston A10/antineoplaston As2-1

Drug Profile

Antineoplaston A10/antineoplaston As2-1

Alternative Names: A10; A10 I; ANP; Antineoplastons A10/AS2-1; Antineoplastons therapy; AS2-1; Astugenal (AS2-1); Atengenal (A10); NSC-620261; NSC-648539

Latest Information Update: 18 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Burzynski Research Institute
  • Class Amino acids; Antineoplastics; Antineoplastons; Benzeneacetamides; Phenylacetates; Piperidones
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anaplastic astrocytoma; Glioma
  • No development reported Cancer

Most Recent Events

  • 01 Apr 2017 Burzynski Research Institute terminated a phase II trial due to slow accrual in Glioma (Second-line therapy or greater, In children, In adolescents) in USA (IV) (NCT00003476)
  • 07 Dec 2016 Discontinued - Phase-II for Glioma (Metastatic disease, Adjuvant therapy) in USA (IV) (NCT02988726)
  • 01 Apr 2016 Burzynski Research Institute initiates a phase-II clinical trial in Glioma (In infants, In children, In adolescents, In adults, In the elderly) in USA (IV) (NCT02742883)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top